TABLE 3.
Variables | HR (95% CI) | p-value |
Baseline | ||
Age | 1.03 (0.97–1.10) | 0.37 |
Male | 1.57 (0.52–6.78) | 0.46 |
Treated with pirfenidone | 1.13 (0.26–3.39) | 0.84 |
Treated with CS and/or IS | 2.09 (0.66–5.78) | 0.20 |
FVC % predicted | 0.96 (0.93–0.99) | <0.01 |
DLCO % predicted | 0.91 (0.85–0.96) | <0.01 |
CPI | 1.12 (1.05–1.21) | <0.01 |
Serum KL-6 100 U·mL−1 | 1.02 (0.96–1.06) | 0.51 |
Serum SP-D 10 ng·mL−1 | 1.01 (0.99–1.02) | 0.39 |
6 month change | ||
FVC % predicted | 0.89 (0.80–0.99) | 0.03 |
DLCO % predicted | 0.99 (0.90–1.12) | 0.85 |
Serum KL-6 100 U·mL−1 | 1.08 (1.02–1.14) | 0.02 |
Serum SP-D 10 ng·mL−1 | 1.03 (1.00–1.05) | 0.07 |
HR: hazard ratio; CS: corticosteroid; IS: immunosuppressive agent; FVC: forced vital capacity; DLCO: diffusing capacity of the lung for carbon monoxide; CPI: composite physiological index; KL-6: Krebs von den Lungen-6; SP-D: surfactant protein-D.